Extract from the Register of European Patents

EP About this file: EP3498301

EP3498301 - KIT COMPRISING IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  05.05.2023
Database last updated on 11.04.2026
FormerGrant of patent is intended
Status updated on  02.08.2022
FormerExamination is in progress
Status updated on  23.10.2020
FormerRequest for examination was made
Status updated on  06.12.2019
FormerThe application has been published
Status updated on  17.05.2019
Most recent event   Tooltip05.05.2023Application deemed to be withdrawnpublished on 07.06.2023  [2023/23]
Applicant(s)For all designated states
PIERRE FABRE MEDICAMENT
Les Cauquillous
81500 Lavaur / FR
[2022/11]
Former [2019/25]For all designated states
PIERRE FABRE MEDICAMENT
45 place Abel Gance
92100 Boulogne-Billancourt / FR
Inventor(s)01 / RILATT, Ian
67 chemin de Montplaisir
81100 CASTRES / FR
02 / PEREZ, Michel
45 chemin de la Pique
81100 CASTRES / FR
03 / GOETSCH, Liliane
15 route de Cluze
74130 AYZE / FR
04 / BROUSSAS, Matthieu
13b rue du Lieutenant Bovagne Immeuble les
Terrasses
01420 SEYSSEL / FR
05 / BEAU-LARVOR, Charlotte
156 rue du Champs à la Moine Hameau de Vigny
74520 JONZIER EPAGNY / FR
06 / HAEUW, JEAN-FRANCOIS
30 Domaine du Salève Route du Salève
74160 BEAUMONT / FR
07 / CHAMPION, Thierry
4 avenue de la gare Immeuble le Quai d'Armand
74160 SAINT JULIEN EN GENEVOIS / FR
08 / ROBERT, Alain
12 rue de Romagny
74100 ANNEMASSE / FR
09 / LAMOTHE, Marie
2 Route des Mines
81360 Montredon Labessonie / FR
 [2020/16]
Former [2019/25]01 / RILATT, Ian
67 chemin de Montplaisir
81100 CASTRES / FR
02 / PEREZ, Michel
45 chemin de la Pique
81100 CASTRES / FR
03 / GOETSCH, Liliane
15 route de Cluze
74130 AYZE / FR
04 / BROUSSAS, Matthieu
13b rue du Lieutenant Bovagne Immeuble les
Terrasses
01420 SEYSSEL / FR
05 / BEAU-LARVOR, Charlotte
156 rue du Champs à la Moine Hameau de Vigny
74520 JONZIER EPAGNY / FR
06 / HAEUW, JEAN-FRANCOIS
30 Domaine du Salève Route du Salève
74160 BEAUMONT / FR
07 / CHAMPION, Thierry
4 avenue de la gare Immeuble le Quai d'Armand
74160 SAINT JULIEN EN GENEVOIS / FR
08 / ROBERT, Alain
12 rue de Romagny
74100 ANNEMASSE / FR
Representative(s)Regimbeau
20, rue de Chazelles
75847 Paris Cedex 17 / FR
[2019/25]
Application number, filing date19154902.127.04.2015
[2019/25]
Priority number, dateEP2014030562025.04.2014         Original published format: EP 14305620
[2019/25]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3498301
Date:19.06.2019
Language:EN
[2019/25]
Search report(s)(Supplementary) European search report - dispatched on:EP27.03.2019
ClassificationIPC:A61K47/50, A61P35/00
[2019/25]
CPC:
A61K47/6849 (EP,KR,RU,US); A61K39/395 (IL,KR); A61K31/4015 (CN);
A61K38/08 (CN); A61K47/68031 (EP,CN,IL,KR,RU,US); A61K47/6889 (KR);
A61P35/00 (EP,KR); C07K16/2863 (RU,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/02]
Former [2019/25]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Validation statesMA31.01.2019
TitleGerman:KIT MIT IGF-1R-ANTIKÖRPER-WIRKSTOFFKONJUGAT UND DESSEN VERWENDUNG BEI DER BEHANDLUNG VON KREBS[2019/25]
English:KIT COMPRISING IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER[2019/25]
French:KIT COMPRENANT UN CONJUGUÉ ANTICORPS-MÉDICAMENT IGF-1R ET SON UTILISATION POUR LE TRAITEMENT DU CANCER[2019/25]
Biological materialThis application mentions deposited biological material, check the file for details
Examination procedure04.12.2019Examination requested  [2020/02]
04.12.2019Date on which the examining division has become responsible
30.03.2020Amendment by applicant (claims and/or description)
27.10.2020Despatch of a communication from the examining division (Time limit: M06)
26.07.2021Reply to a communication from the examining division
20.09.2021Despatch of a communication from the examining division (Time limit: M06)
21.03.2022Reply to a communication from the examining division
03.08.2022Communication of intention to grant the patent
14.12.2022Application deemed to be withdrawn, date of legal effect  [2023/23]
19.01.2023Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time  [2023/23]
Parent application(s)   TooltipEP15720045.2  / EP3134124
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
26.07.2021Request for further processing filed
26.07.2021Full payment received (date of receipt of payment)
Request granted
04.08.2021Decision despatched
The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
30.03.2020Request for further processing filed
30.03.2020Full payment received (date of receipt of payment)
Request granted
10.07.2020Decision despatched
Fees paidRenewal fee
31.01.2019Renewal fee patent year 03
31.01.2019Renewal fee patent year 04
31.01.2019Renewal fee patent year 05
30.03.2020Renewal fee patent year 06
24.03.2021Renewal fee patent year 07
25.03.2022Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A] WO2012142164  (US HEALTH et al.)
 [A] WO2010146059  (HOFFMANN LA ROCHE et al.)
 [A]   DORONINA S O ET AL: "Development of potent monoclonal antibody auristatin conjugates for cancer therapy", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 21, no. 7, 1 July 2003 (2003-07-01), pages 778 - 784, XP002280966, ISSN: 1087-0156, DOI: 10.1038/NBT832

DOI:   http://dx.doi.org/10.1038/nbt832
by applicantEP0451216
 EP0682040
 EP0939127
 EP0566647
 US5530101
 US6180370
 US5585089
 US5693761
 US5639641
 US6054297
 US5886152
 US5877293
 US7521541
 US7723485
 WO2009052249
   LEFRANC M.-P., IMMUNOLOGY TODAY, vol. 18, 1997, pages 509
   LEFRANC M.-P., THE IMMUNOLOGIST, vol. 7, 1999, pages 132 - 136
   LEFRANC, M.-P.; POMMIE, C.; RUIZ, M.; GIUDICELLI, V.; FOULQUIER, E.; TRUONG, L.; THOUVENIN-CONTET, V.; LEFRANC, DEV., COMP. IMMUNOL., vol. 27, 2003, pages 55 - 77
   RUIZ, M.; LEFRANC, M.-P., IMMUNOGENETICS, vol. 53, 2002, pages 857 - 883
   KAAS, Q.; LEFRANC, M.-P., CURRENT BIOINFORMATICS, vol. 2, 2007, pages 21 - 30
   KAAS, Q.; RUIZ, M.; LEFRANC, M.-P.: "T cell receptor and MHC structural data", NUCL. ACIDS. RES., vol. 32, 2004, pages D208 - D210
   KABAT ET AL.: "Sequences of proteins of immunological interest", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, NIH
   SMITH; WATERMAN, AD. APP. MATH., vol. 2, 1981, pages 482
   NEDDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443
   PEARSON; LIPMAN, PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 2444
   TATUSOVA ET AL.: "Blast 2 sequences - a new tool for comparing protein and nucleotide sequences", FEMS MICROBIOL., vol. 174, 1999, pages 247 - 250
   T.W. GREENE: "Protective Groups in Organic Synthesis", 2006, JOHN WILEY & SONS
   P.J. KOCIENSKI: "Protecting Groups", 1994, THIEME VERLAG
   LIU; MAY, MABS, vol. 4, 2012, pages 17 - 23
   JUNUTULA ET AL., NATURE BIOTECH., vol. 26, no. 8, 2008, pages 925 - 932
   DORNAN ET AL., BLOOD, vol. 114, no. 13, 2009, pages 2721 - 2729
   KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497
   HARLOW; LANE: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY, COLD SPRING HARBOR, pages: 726
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.